References
Kirshner, J., Heckler, C., Janelsins, M., Dakhil, S., Hopkins, J., Coles, C., & Morrow, G. (2012). Prevention of pegfilgrastim-induced bone pain: A phase III double-blind placebo-controlled randomized clinical trial to the University of Rochester Cancer Center Clinical Community Oncology Program Research Base. Journal of Clinical Oncology, 30, 1974-1979.
Kirshner, J., Heckler, C., Reichel, T., McAuliffe, C., & Morrow, G. (2011). A phase II study of loratidine (L) to prevent pegfilgrastim-induced pain (PIP). Journal of Clinical Oncology, 29(15, Suppl.), e19704.
Kirshner, J., Heckler, C., Reichel, T., & Morrow, G. (2010). A phase II study of loratidine (L) and naproxen (N) to prevent pegfilgrastim-induced pain (PIP). Journal of Clinical Oncology, 30(15, Suppl.), e19510.
Pinto, L., Liu, Z., Doan, Q., Bernal, M., Dubois, R., & Lyman, G. (2007). Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia, and bone pain: A meta-analysis of randomized controlled trials. Current Medical Research and Opinion, 23, 2283-2295. doi:10.1185/30079907x219599
Citron, M., Berry, D., Cirrincione, C., Hudis, C., Winer, E., Gradishar, W., … Norton, L. (2003). Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/Cancer and Leukemia Group B Trail 9741. Journal of Clinical Oncology, 21, 1431-1439.
Gregory, S., Schwartzberg, L., Mo, M., Sierra, J., & Vogel, C. (2010). Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: A retrospective analysis. Community Oncology, 7, 297-308.
Kirshner, J., Heckler, C., Janelsins, M., Dakhil, S., Hopkins, J., Coles, C., & Morrow, G. (2012). Prevention of pegfilgrastim-induced bone pain: A phase III double-blind placebo-controlled randomized clinical trial to the University of Rochester Cancer Center. Journal of Clinical Oncology, 30, 1974-1979.
Kirshner, J., Heckler, C., Reichel, T., McAuliffe, C., & Morrow, G. (2011). A phase II study of loratidine (L) to prevent pegfilgrastim-induced pain (PIP). Journal of Clinical Oncology, 29(15, Suppl.), e19704.
Kirshner, J., Heckler, C., Reichel, T., & Morrow, G. (2010). A phase II study of loratidine (L) and naproxen (N) to prevent pegfilgrastim-induced pain (PIP). Journal of Clinical Oncology, 30(15, Suppl.), e19510.
Kirshner, J., Hickok, J., & Hofman, M. (2007). Pegfilgrastim-induced bone pain: Incidence, risk factors, and management in a community practice. Community Oncology, 4, 455-459.
Kubista, E., Glaspy, J., Holmes, F.A., Green, M.D., Hackett, J., & Neumann, T. (2003). Bone pain associated with once-per cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clinical Breast Cancer, 3, 391-398.
Kummel, S., Krocker, J., Kohls, A., Breitbach, G.P., Morack, G., Budner, M., … Elling, D. (2006). Randomized trial: Survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. British Journal of Cancer, 94, 1237-1244.
National Comprehensive Cancer Network. (2013). NCCN Clinical Practice Guidelines in Oncology®. Myeloid growth factors [v.2.2013]. Retrieved from
http://bit.ly/N8tXMp
Pinto, L., Liu, Z., Doan, Q., Bernal, M., Dubois, R., & Lyman, G. (2007). Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia, and bone pain: A meta-analysis of randomized controlled trials. Current Medical Research and Opinion, 23, 2283-2295.
Smith, T.J., Khatcheressian, J., Lyman, G.H., Armitage, J.O., Balducci, L., Bennett, C.C., … Wolf, A.C. (2006). 2006 update of recommendations for the use of white blood cell growth factors. Journal of Clinical Oncology, 24, 3187-3205.